Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant
US12365706B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 15, 2020 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | Feb 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.